Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PFE

Pfizer Inc

Oct 31 • 09:41AM ET

24.39

+0.10 0.41 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: BMY MRK SNY AMGN ABBV NVS JNJ GSK LLY AZN

| Held by: VTI VOO IVV SPY VTV XLV VYM VHT DVY FDL

Scroll to Statements

Index	S&P 500	P/E	12.97	EPS (ttm)	1.88	Insider Own	0.11%	Shs Outstand	5.68B	Perf Week	-1.49%
Market Cap	138.67B	Forward P/E	7.80	EPS next Y	3.13	Insider Trans	0.00%	Shs Float	5.68B	Perf Month	-9.93%
Enterprise Value	187.54B	PEG	-	EPS next Q	0.63	Inst Own	66.81%	Short Float	2.06%	Perf Quarter	3.65%
Income	10.73B	P/S	2.17	EPS this Y	-2.29%	Inst Trans	-0.51%	Short Ratio	2.26	Perf Half Y	0.79%
Sales	63.83B	P/B	1.56	EPS next Y	2.90%	ROA	5.08%	Short Interest	116.82M	Perf YTD	-8.07%
Book/sh	15.60	P/C	10.47	EPS next 5Y	-0.26%	ROE	12.16%	52W High	28.64 -14.84%	Perf Year	-14.30%
Cash/sh	2.33	P/FCF	11.15	EPS past 3/5Y	-28.69% -13.27%	ROIC	7.34%	52W Low	20.92 16.61%	Perf 3Y	-47.05%
Dividend Est.	1.70 (6.96%)	EV/EBITDA	7.30	Sales past 3/5Y	-7.84% 9.10%	Gross Margin	67.34%	Volatility	1.36% 1.83%	Perf 5Y	-32.13%
Dividend TTM	1.71 (7.01%)	EV/Sales	2.94	EPS Y/Y TTM	510.84%	Oper. Margin	29.60%	ATR (14)	0.44	Perf 10Y	-24.42%
Dividend Ex-Date	Nov 07, 2025	Quick Ratio	0.85	Sales Y/Y TTM	14.72%	Profit Margin	16.81%	RSI (14)	44.07	Recom	2.46
Dividend Gr. 3/5Y	2.49% 2.97%	Current Ratio	1.16	EPS Q/Q	11938.10%	SMA20	-1.79%	Beta	0.51	Target Price	28.67
Payout	120.11%	Debt/Eq	0.70	Sales Q/Q	10.31%	SMA50	-1.62%	Rel Volume	0.91	Prev Close	24.29
Employees	81000	LT Debt/Eq	0.65	Earnings	Nov 04 BMO	SMA200	-1.13%	Avg Volume	51.58M	Price	24.39
IPO	Jan 17, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.39% 8.06%	Trades		Volume	3,588,107	Change	0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$24
Dec-10-24	Resumed	BofA Securities	Neutral	$29
Nov-15-24	Initiated	Wolfe Research	Underperform	$25
Oct-25-24	Resumed	Citigroup	Neutral	$30
Oct-17-24	Initiated	Bernstein	Mkt Perform	$32
Aug-07-24	Upgrade	Daiwa Securities	Neutral → Outperform
Mar-22-24	Downgrade	Argus	Buy → Hold
Feb-23-24	Initiated	Guggenheim	Buy	$36
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$32
Oct-20-23	Resumed	UBS	Neutral	$36 → $34
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$38 → $39
Jul-17-23	Reiterated	JP Morgan	Neutral	$45 → $41
Jul-14-23	Initiated	HSBC Securities	Buy	$50
Jun-29-23	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $40
May-11-23	Downgrade	Daiwa Securities	Outperform → Neutral	$38
Mar-06-23	Initiated	Jefferies	Hold	$43
Feb-07-23	Upgrade	Daiwa Securities	Neutral → Outperform	$51
Jan-26-23	Downgrade	UBS	Buy → Neutral	$55 → $47
Jan-17-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$54 → $50
Jan-04-23	Downgrade	BofA Securities	Buy → Neutral	$60

Show Previous Ratings

Today 08:52AM	Novo Nordisk cuts 9,000 jobs as it looks to new weight-loss drugs (Reuters Videos)
08:25AM	Pfizer Faces Off With Novo Nordisk Over Metsera Bid (GuruFocus.com)
08:20AM	AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings. (Barrons.com)
Oct-30-25 10:30PM	Jim Cramer on Pfizer: "The Drug Stocks Are Just in a World of Hurt, and This One Continues to Be There" (Insider Monkey)
06:00PM	The Day Pharmas Weight-Loss Gold Rush Intensified (The Wall Street Journal)
05:50PM	Loading…
05:50PM	Pfizer Fires Back as Novo Nordisk Hijacks Its $8.5 Billion Metsera Deal (GuruFocus.com)
04:35PM	Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle (The Wall Street Journal)
04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
03:51PM	Meta Sells $30 Billion of Bonds as AI Frenzy Fuels Record Orders (Bloomberg)
03:03PM	Novo Nordisk takes on Pfizer in bid for obesity biotech Metsera (Reuters Videos)
02:16PM	Pfizer said to mull suing Novo Nordisk over Metsera bid (Investing.com)
02:11PM	Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. (Barrons.com)
02:05PM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
01:44PM	Analyst Report: Haleon plc (Morningstar Research)
01:31PM	Bidding war rises over weight loss drug that could prevent Ozempic face (The Telegraph)
01:19PM	Loading…
01:19PM	Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera (Investor's Business Daily)
01:11PM	Chipotle drags fast casual stocks lower, Meta reports raising $125B (Yahoo Finance Video)
12:52PM	Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera (The Wall Street Journal)
11:23AM	Novo Nordisk locks horns with Pfizer in late bid for Metsera (Pharmaceutical Technology)
10:41AM	Stocks to Watch Thursday: Eli Lilly, Metsera, Navan, Chipotle (The Wall Street Journal)
10:39AM	Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war (Associated Press Finance)
10:32AM	BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View (Zacks)
10:04AM	Novo, Pfizer Square Off Over Metsera in Obesity-Drug Tussle (Bloomberg)
09:56AM	Singapore Approves Latest Pfizer/BioNTech COVID-19 Vaccine for All Ages (Insider Monkey)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
09:25AM	Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook (Yahoo Finance Video)
09:22AM	Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal (Barrons.com)
09:15AM	What Analyst Projections for Key Metrics Reveal About Pfizer (PFE) Q3 Earnings (Zacks)
09:13AM	Novo Nodrisk stock dips on aggressive odder to buy Metsera, reckless says Pfizer (Investing.com)
08:20AM	Novo Nordisk launches bidding war with Pfizer for obesity drugmaker Metsera (AFP)
07:57AM	Loading…
07:57AM	Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings (The Wall Street Journal)
07:45AM	Merck (MRK) Q3 Earnings and Revenues Beat Estimates (Zacks)
07:11AM	Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker. (Barrons.com)
06:57AM	Pfizer Addresses Proposal for Metsera (Business Wire)
06:51AM	Merck Stock Falls After Earnings. Keytruda Sales Top $8 Billion for First Time. (Barrons.com)
06:32AM	Pfizer and Roche place $10bn bets on obesity and liver disease therapies as Trump tightens grip on drug pricing and manufacturing (Pharmaceutical Technology)
06:23AM	Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera (The Wall Street Journal)
04:15AM	Prediction: Putting $1,000 Into These Dividend Stocks Could Pay Off for Years (Motley Fool)
Oct-29-25 07:00PM	2 High-Yield Stocks With Fresh Catalysts (Motley Fool)
04:45PM	Eli Lilly Reports Earnings Thursday as Investors Await Trump Drug Pricing Deal (Barrons.com)
04:30PM	Merck Reports Earnings Under Shadow of Keytruda Patent Cliff. What to Expect. (Barrons.com)
11:18AM	Berenberg Bank Maintains a Hold on Pfizer Inc (PFE), Ahead of Q3 Earnings (Insider Monkey)
09:27AM	Pfizer Stock: Is Wall Street Bullish or Bearish? (Barchart)
09:04AM	Stock market: Yahoo Finance Invest features exclusive conversations on AI, crypto, and the economy (Yahoo Finance)
08:22AM	What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree? (Zacks)
Oct-28-25 05:45PM	Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
03:15PM	5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade (24/7 Wall St.)
01:25PM	3 Stocks Under $30: Where to Put $1,000 to Work Today (24/7 Wall St.)
12:37PM	Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know (Zacks)
11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
10:40AM	Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report? (Zacks)
10:00AM	Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline (Zacks)
Oct-27-25 02:00PM	3 Dividend-Paying Drug Stocks to Buy at a Discount (Motley Fool)
12:21PM	What Is 1 of the Best Pharmaceutical Stocks to Buy Now? (Motley Fool)
12:15PM	Should You Buy Pfizer Stock Before Nov. 4? (Motley Fool)
09:17AM	Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings? (Zacks)
08:30AM	Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology (PR Newswire)
08:00AM	2 Unstoppable Health Care Giants to Buy Right Now for Less Than $1,000 (Motley Fool)
05:43AM	Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030 (Motley Fool)
04:30AM	3 Healthcare Stocks Paying the Highest Dividends of 2025 (Motley Fool)
04:00AM	Mercks oncology prospects could portend a post-Keytruda future (Pharma Voice)
Oct-26-25 10:19AM	More Rate Cuts Are Coming: Grab 6% High-Yield S&P 500 Stocks Now (24/7 Wall St.)
07:25AM	Pfizer Inc. (PFE) and Astellas Pharma Announce Survival Results from Phase 3 EMBARK Study (Insider Monkey)
04:00AM	Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever. (Motley Fool)
Oct-25-25 07:00AM	2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever (Motley Fool)
Oct-24-25 04:12PM	Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue (Investor's Business Daily)
12:07PM	A GSK Cancer Drug Is Making a Comeback. It's So-So News for the Stock. (Barrons.com)
11:30AM	PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now? (Zacks)
09:29AM	Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings (Zacks)
09:00AM	Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
04:45AM	Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue (The Wall Street Journal)
Oct-23-25 06:51PM	Dividend Stocks Arent Just for Income Investors. Heres Another Reason to Buy Them. (Barrons.com)
12:53PM	Roche in ongoing discussions with US government over drug pricing, CEO says (Pharmaceutical Technology)
11:15AM	Medpace Holdings' Good Quarter Is Another Sign Biotech Is Back (Barrons.com)
10:39AM	Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
08:09AM	The Other Reason to Buy Dividend Stocks (Barrons.com)
05:24AM	Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue (The Wall Street Journal)
03:30AM	The Other Reason to Buy Dividend Funds (Barrons.com)
Oct-22-25 10:29AM	AbbVie Up More Than 30% in 6 Months: How to Play the Stock (Zacks)
06:27AM	Thermo Scientific Revenue Rises, Boosted by Life Sciences Business (The Wall Street Journal)
Oct-21-25 01:35PM	Danaher Third-Quarter Earnings Rise; Pharma R&D Spend Expected to Rebound (The Wall Street Journal)
08:58AM	Will BMY's Growth Portfolio Drive Third-Quarter Results? (Zacks)
07:37AM	2 Mega-Dividend Stocks With Yields As High As 7% (Motley Fool)
06:23AM	Danaher Sales and Profit Rise on Bioprocessing Momentum (The Wall Street Journal)
05:52AM	Pfizer Inc. (PFE) Announces Positive Results From its Phase 3 HER2CLIMB-05 Trial (Insider Monkey)
Oct-20-25 02:03PM	Elon Musk takes shot at rival facing major problem (TheStreet)
10:15AM	Pfizer's Q3 Non-Oncology Performance: Here's What to Expect (Zacks)
10:10AM	How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results? (Zacks)
10:10AM	Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings (Zacks)
Oct-19-25 10:57AM	2 High-Yield Dividend Stocks Too Cheap to Ignore (Motley Fool)
04:15AM	XTANDI Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer (Business Wire)
02:30AM	Pfizer's BRAFTOVI + MEKTOVI Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer (Business Wire)
Oct-18-25 10:35AM	Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients (Investor's Business Daily)
10:30AM	PADCEV Plus KEYTRUDA, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer (PR Newswire)
Oct-17-25 06:42PM	Top Analyst Reports for Home Depot, Boeing & Progressive (Zacks)
05:45PM	Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
02:02PM	Biotech Is Finally Rallying. Why Mizuhos Jared Holz Is Optimistic This Time. (Barrons.com)
12:11PM	Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings? (Zacks)
09:00AM	Precision Oncology Approaches Drive $312B Market Transformation (PR Newswire)
03:31AM	Novo, Lilly Fall as Trump Touts Much Lower Ozempic Price (Bloomberg)

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dolsten Mikael	Former Officer	May 23 '25	Proposed Sale	23.09	59,781	1,380,632		May 23 10:54 AM
Dolsten Mikael	Former Officer	May 05 '25	Proposed Sale	23.87	55,000	1,312,736		May 05 04:45 PM
DAMICO JENNIFER B.	SVP & Controller	Mar 04 '25	Sale	25.93	2,500	64,825	11,850	Mar 06 01:57 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 27 '25	Option Exercise	31.31	22,416	701,845	31,063	Mar 03 05:39 PM
SUSMAN SALLY	Executive Vice President	Feb 27 '25	Option Exercise	31.31	85,182	2,667,048	250,866	Mar 03 05:38 PM
SAHNI PAYAL	Executive Vice President	Feb 27 '25	Option Exercise	31.31	19,054	596,581	44,242	Mar 03 05:38 PM
McDermott Michael	Executive Vice President	Feb 27 '25	Option Exercise	31.31	48,419	1,515,999	122,413	Mar 03 05:37 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 27 '25	Option Exercise	31.31	156,914	4,912,977	309,790	Mar 03 05:37 PM
Fonseca Lidia	Executive Vice President	Feb 27 '25	Option Exercise	31.31	72,629	2,274,014	111,534	Mar 03 05:36 PM
BOURLA ALBERT	Chairman & CEO	Feb 27 '25	Option Exercise	31.31	582,823	18,248,188	931,744	Mar 03 05:36 PM
McDermott Michael	Executive Vice President	Feb 22 '25	Option Exercise	30.17	11,125	335,641	87,636	Feb 25 07:38 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 22 '25	Option Exercise	30.17	8,741	263,716	17,602	Feb 25 07:38 PM
BOURLA ALBERT	Chairman & CEO	Feb 22 '25	Option Exercise	30.17	238,399	7,192,498	570,436	Feb 25 07:06 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 22 '25	Option Exercise	30.17	85,824	2,589,310	232,775	Feb 25 07:05 PM
SAHNI PAYAL	Executive Vice President	Feb 22 '25	Option Exercise	30.17	12,714	383,581	37,099	Feb 25 07:04 PM
SUSMAN SALLY	Executive Vice President	Feb 22 '25	Option Exercise	30.17	63,573	1,917,997	225,184	Feb 25 07:02 PM
BOSHOFF CHRISTOFFEL	President, R&D	Feb 22 '25	Option Exercise	30.17	8,741	263,716	159,085	Feb 25 06:58 PM
BLAYLOCK RONALD E	Director	Feb 13 '25	Buy	25.65	19,457	499,072	27,707	Feb 14 05:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PFE

Pfizer Inc

Upgrade your FINVIZ experience